Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma.
To investigate the role of the p53 tumor-suppressor gene in the development of human melanoma, loss of heterozygosity (LOH) of p53 was studied in 46 cases of melanoma by a polymerase-chain-reaction/restriction-fragment-length polymorphism (PCR/RFLP) analysis, and p53 mutations were assessed in 51 cases of melanoma by a polymerase-chain-reaction/single-strand-conformation polymorphism (PCR/SSCP) analysis. Frozen tumors and paraffin samples were used in the study. We were not able to detect any allelic loss in 12BstUI informative cases or any single mutation in exons 5 to 8 of the p53 gene. Our results, together with other findings at the DNA level, suggest that the p53 gene appears not to be commonly involved in the development of melanoma, at least by its most frequent mechanisms of deletion of one allele and/or mutation in the other.
Castresana
J S
JS
Molecular Neuro-Oncology Laboratory, Massachusetts General Hospital, Charlestown 02129.
Rubio
M P
MP
Vázquez
J J
JJ
Idoate
M
M
Sober
A J
AJ
Seizinger
B R
BR
Barnhill
R L
RL
D001483:Base Sequence; D002872:Chromosome Deletion; D015972:Gene Expression Regulation, Neoplastic; D016158:Genes, p53; D006579:Heterozygote; D006801:Humans; D008545:Melanoma / Q000235:genetics*; D008969:Molecular Sequence Data; D017354:Point Mutation; D016133:Polymerase Chain Reaction; D012150:Polymorphism, Restriction Fragment Length; D012878:Skin Neoplasms / Q000235:genetics*